#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic lupus erythematosus Leukaemia Hepatic cirrhosis Loeys-Dietz syndrome Neurofibromatosis Malformation venous Hyperphagia Mastocytosis Oesophageal carcinoma Haemophilia B with anti factor IX Neuroendocrine cell hyperplasia of infancy Diffuse large B-cell lymphoma B-cell small lymphocytic lymphoma refractory Cholangiosarcoma Skin angiosarcoma More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Trials in Disease Bronchiolitis obliterans syndrome – Life with Disease Mucopolysaccharidosis I – Life with Disease Ornithine transcarbamoylase deficiency – Treatment Langerhans’ cell histiocytosis – Trials in Disease Toxic epidermal necrolysis – Diagnostics Turner’s syndrome – Diagnostics Osteosarcoma recurrent – Treatment Pleural mesothelioma malignant – Life with Disease Metachromatic leukodystrophy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sirexatamab Sotrovimab F510/08 LUMC-BOB1-B7-TCR.1 Lysine Aspirin Other Immunosuppressants L-ALANINE Human Coagulation Factor Vii GSKVX000000025896 Oregovomab ABBV-8736 RO7288817 XELAFASLATIDE Fluorescein Sodium Bi 3032950 Levodropropizine Cpft Trifluoroacetate Dexmedetomidine Nifedipine Mifepristone More therapies…

    Learn about Your Condition

    Hepatic cirrhosis Autism spectrum disorder Chronic fatigue syndrome Hyperadrenocorticism Hypoparathyroidism Post-traumatic stress disorder Fontan procedure Autoimmune disorder Dilated cardiomyopathy Thrombosis prophylaxis Arthritis infective Paget's disease of the vulva Primary hyperaldosteronism Soft tissue sarcoma Dupuytren's contracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Macular oedema

  • Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Macular oedema
    Investigated Drugs:
    • Humanised Igg2 Monoclonal Antibody Against Interleukin-6
    Czechia France Germany Italy Poland Portugal +1

  • Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Choroidal neovascularisation
    • Macular oedema
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Poland

  • Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Retinal vein occlusion
    Investigated Drugs:
    • Ranibizumab
    Austria Germany

  • Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Macular oedema
    Investigated Drugs:
    • Humanised Igg2 Monoclonal Antibody Against Interleukin-6
    Austria Italy The Netherlands Poland Portugal

  • Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Retinal vein occlusion
    Investigated Drugs:
    • Fluorescein Sodium
    • Aflibercept
    Austria Bulgaria Czechia Estonia France Germany +8

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!